Stratipath
Stage
Series A | AliveTotal Raised
$2.3MLast Raised
$2.3M | 4 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-44 points in the past 30 days
About Stratipath
Stratipath specializes in AI-based precision diagnostics within the healthcare sector, focusing on cancer treatment decision support. The company offers cloud-based SaaS solutions that leverage deep learning technologies to provide risk profiling of tumors, particularly for breast cancer. Stratipath's services are utilized by healthcare providers, including oncology clinics and pathology labs, to enhance the diagnostic process. It is based in Sweden.
Loading...
Stratipath's Product Videos
Stratipath's Products & Differentiators
Stratipath Breast
Risk profiling of Breast cancer tumours of intermediate risk. 50% of all breast cancer tumours are in the intermediate category. To decide upon chemotherapy or not, oncologists need to get precision diagnosis of the tumour.
Loading...
Research containing Stratipath
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Stratipath in 2 CB Insights research briefs, most recently on Nov 27, 2024.
Aug 10, 2023
The oncology tech market mapExpert Collections containing Stratipath
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Stratipath is included in 3 Expert Collections, including Artificial Intelligence (AI).
Artificial Intelligence (AI)
16,409 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
571 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Stratipath Patents
Stratipath has filed 2 patents.
The 3 most popular patent topics include:
- machine learning
- oncology
- anatomical pathology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/12/2023 | Barcodes, Image processing, Oncology, Machine learning, Anatomical pathology | Application |
Application Date | 6/12/2023 |
|---|---|
Grant Date | |
Title | |
Related Topics | Barcodes, Image processing, Oncology, Machine learning, Anatomical pathology |
Status | Application |
Latest Stratipath News
Sep 4, 2025
PathAI BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered digital pathology solutions and the developer of the market-leading AISight Dx1 Image Management System (IMS), today announced new partnerships with three cutting-edge AI pathology innovators: Mindpeak , Stratipath , and Primaa to enable their AI products to be available through the AISight Dx IMS. This strategic expansion underscores PathAI’s commitment to delivering validated digital pathology workflows in Europe; further reinforcing its commitment to offering the most versatile, reliable, and interoperable IMS on the market. Mindpeak’s 11 CE-IVD-marked AI portfolio spans breast cancer (HER2, ER, PR, Ki-67) and lung PD-L1, complemented by RUO assays for prostate and other tumor types - all accessible through PathAI’s platform to enable standardized biomarker quantification. Stratipath provides the first CE-IVD marked AI-based solution for prognostic risk profiling of breast cancer using routine histopathology slides. Primaa, specializing in AI-guided tools for dermatopathology and breast pathology, now delivers seamless integration into AISight Dx for high-throughput diagnostic accuracy. “With these partnerships, PathAI continues to build the most comprehensive CE-IVD digital pathology ecosystem,” said Andy Beck, MD, PhD, Co-founder and CEO of PathAI. “Our expanded AI portfolio now including Mindpeak, Stratipath, and Primaa brings validated algorithms directly into the hands of pathologists via AISight Dx, accelerating adoption and reinforcing trust in digital workflows.” Through AISight Dx, pathologists will benefit from: AI-powered overlays and CE-IVD algorithm results, embedded directly into diagnostic case review workflows. Seamless integration with laboratory and hospital IT systems via AISight Link - a secure, open API. A clinically endorsed algorithm catalog, including tools for biomarker quantification, tissue classification, and diagnostic decision support. For more information about PathAI, AISight Dx, or the expanding algorithm catalog, please contact digital.dx@pathai.com or visit pathai.com . 1 AISight® Dx is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland and FDA-cleared for primary diagnosis in the US. About the Partners Mindpeak Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak’s AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications. Stratipath Stratipath is an AI company dedicated to revolutionising cancer treatment decisions and enhancing patient outcomes by assisting physicians in delivering optimal treatment to every patient. Stratipath’s pioneering solutions and AI-based precision diagnostic software platform transform tissue sample analysis, enabling breakthrough insights for enhanced and faster patient stratification across healthcare, clinical trials, and drug development. By expanding the reach of precision medicine, Stratipath aims to make this advanced healthcare approach accessible to a wider patient population. Founded as a spin-out of Karolinska Institutet in Stockholm, Sweden, Stratipath is built upon years of groundbreaking research and development. For more information, please visit www.stratipath.com . Primaa Primaa’s advanced platform leverages AI algorithms to enhance the accuracy and efficiency of biomarkers detection for dermatopathology and breast pathology and ultimately redefine how pathologists are approaching tissue lesions diagnosis. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit pathai.com . Media Contact
Stratipath Frequently Asked Questions (FAQ)
What is Stratipath's latest funding round?
Stratipath's latest funding round is Series A.
How much did Stratipath raise?
Stratipath raised a total of $2.3M.
Who are the investors of Stratipath?
Investors of Stratipath include Sven Hagstromer, Creades, Nascent Invest and KI Innovations.
Who are Stratipath's competitors?
Competitors of Stratipath include Ibex and 5 more.
What products does Stratipath offer?
Stratipath's products include Stratipath Breast.
Loading...
Compare Stratipath to Competitors
biomy provides AI analysis software for cancer microenvironments. The company offers AI-based spatial analysis technology that aids in understanding the tumor microenvironment, predicting patient prognosis, and suggesting appropriate cancer treatments. It serves the biopharma and clinical laboratory sectors. It was founded in 2019 and is based in Tokyo, Japan.
Histai operates as a company focused on artificial intelligence solutions within the digital pathology domain. Its main offerings include a cloud-based digital pathology platform equipped with a whole slide image viewer, collaborative tools, and proprietary algorithms for pathology analysis. The company primarily serves the medical diagnostics and drug development sectors. It was founded in 2023 and is based in San Francisco, California.
Qritive is a company that focuses on AI diagnostics in the healthcare sector, particularly in pathology. They develop AI solutions to assist pathologists in managing workflows from diagnosis to treatment. Their main offerings include a clinical-decision support system for pathologists and an image management platform called Pantheon, which are intended to support cancer diagnoses. It was founded in 2017 and is based in Singapore, Singapore.
Aignostics specializes in AI-powered precision medicine, focusing on the biopharmaceutical industry. The company offers insights by analyzing complex biomedical data, including histopathology, omics, and clinical outcomes, to support drug development and improve patient outcomes. It serves the biopharma sector with solutions for target identification, translational research, trials, and companion diagnostics. It was founded in 2018 and is based in Berlin, Germany.
Imagene AI specializes in AI-based precision oncology within the healthcare sector, focusing on cancer research and diagnostics. The company offers a SaaS platform that integrates imaging, molecular, and clinical data to support biomarker discovery, trial design, and patient identification. Imagene AI primarily serves the healthcare and oncology research sectors with its diagnostic and treatment solutions. It was founded in 2020 and is based in Miami, Florida.
Mechanomind provides AI diagnostics for skin cancer within the healthcare technology sector. The company utilizes computer vision and deep learning to assist in the diagnosis of skin cancer, including the classification of skin tumor subtypes and offering decision support for pathologists. Mechanomind's technology is scanner and image quality agnostic, aimed at maintaining accuracy and efficiency in histopathology analysis. It was founded in 2015 and is based in New York, New York.
Loading...